期刊文献+

托吡酯添加治疗小儿难治性癫痫的临床观察 被引量:1

Appraisal of the curative effect of Topiramate in the adjunctive treatmant of epilepsy in children
下载PDF
导出
摘要 目的研究托吡酯治疗小儿癫痫的疗效与安全性。方法47例癫痫患儿,原来使用的抗癫药种类和剂量不变,将托吡酯作为辅助治疗药物,从0.50~1.00mg/(kg·d)开始,每周增加0.50~1.00mg/(kg·d),目标剂量4.00~9.00mg/(kg·d),根据癫发作情况调整托吡酯剂量。癫痫发作被控制后,原用抗癫药物逐渐减量直至停用。结果患儿治疗3个月后,总有效率,其中简单部分性发作为88.9%,复杂部分性发作为77.8%,症状性癫痫为83.3%。12例患儿在加量期出现轻、中度不良反应,不需特殊处理大多可自行消失。结论托吡酯治疗小儿癫痫疗效确切,安全性高,患儿耐受好。 [Objective ] To study the curative effect and safeness of Topiramate in the adjunctive treatment of epilepsy in children. [Methods] 47 patients with epilepsy were enrolled in the study. The kinds and dosages of antiepileptics formerly used by the patients remained unchanged in the p resent study. Topiramate was then used as an additive remedy, beginning with a dose of 0.50-1.00 mg/(kg·d) per os. The dose was increased by 0.50-1.00 mg/ kg·d every week, aiming at a final dose of 4.00-9.00 mg/(kg·d). When, however, obvious curative effects appeared, the gradual increase in the dosage of the drug was stopped and the dosage on that very day was taken as the maintenance dose thereafter. The antiepileptics formerly used by the patients were given in gradually decreasing doses followed by discontinuation of the drugs after the epilepsy had been controlled. [Results] After 3 months treatment, the overall effective rate of the simple partial seizure (SIX3) was 88.9%, complex partial seizure (CPS) was 77.8%, and symptomatic epilepsy was 83.3%. Adverse reactions were encountered in 12 patients when the doses of Topiramate were steadily increased. These reactions usually disappeared spontaneously demanding no particular managements. [Conclusion] Topiramate was shown to exert defihite curative effects in the treatment of epilepsy in children.
作者 刘红艳
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2008年第11期1610-1612,1614,共4页 China Journal of Modern Medicine
关键词 托吡酯 癫痫 Topiramate epilepsy
  • 相关文献

参考文献9

  • 1王大斌,明萌,齐旭升,王勇,刘新.托吡酯治疗小儿难治性癫部分性发作36例[J].医药导报,2007,26(2):156-158. 被引量:1
  • 2SHANK RP, GARDOCKI JF, STREETER A J, et al. An overview of the preelinieal aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action[J]. Epilepsia, 2000, 41(Suppl1): S3-S9.
  • 3HERRERO A I, DEL OLMO N, GONZALEZ2ESCALADA JR, et al. Two new actions of topiramate: Inhibition of depolarizing GA- BA (A) -mediated responses and activation of a potassium conductance[J]. Nettropharmacology, 2002, 42(2): 210-220.
  • 4FRENCH JA, KANNER A, BAUTIS J, et al. Efficaey and tolerability of the new antiepileptic drugs Ⅱ: treatment of refractory epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American epilepsy society [J]. Neurology, 2004, 62(8): 1261-1273.
  • 5KALIN IN VV, ZHELEZNOVA EV, SOKOLOVA LV, et al. Topamax monotherapy of partial epilepsy [J]. Zh Nevropatol Psikhiatr, 2004, 104(7): 35-38.
  • 6WHELESS J W, NETO W, WAN G S, et aL Topiramate, carbamazepine, and valproate mono therapy: double-blind comparison in children with newly diagnosed epilepsy[J]. Child Neurol, 2004,19(2): 135-141.
  • 7GUERRIN I R, CARPA Y J, GROSELJ J, et al. Topiramate montherapy as broad-specitum antiepileptic drug in anaturalistic clinical setting[J]. Seizure, 2005, 14(6): 371-380.
  • 8VAL ENC IA I, FON S C, KO THARE S V, et al. Efficacy and to lerbility of topiramate in children younger than 2 years old[J]. J Child Neurd, 2005, 20(8): 667-669.
  • 9刘风英,王学峰.托吡酯单药治疗新诊断的癫痫[J].中国新药杂志,2007,16(2):107-111. 被引量:6

二级参考文献28

  • 1SHANK RP, GARDOCKI JF, STREETER AJ,et al. An overview of the preclinical aspects of topiramate : Pharmacology, pharmacokinetics, and mechanism of action [ J ]. Epilepsia, 2000,41( Suppl 1 ) : S3 -S9.
  • 2HERRERO AI, DEL OLMO N, GONZALEZ-ESCALADA JR,et al. Two new actions of topiramate : Inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance [ J ]. Neuropharmacology, 2002,42 ( 2 ) :210 - 220.
  • 3FRENCH JA, KANNER A, BAUTIS J,et al. Efficacy and tolerability of the new antiepileptic drugs Ⅱ: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society[J]. Neurology, 2004, 62(8) :1261 - 1273.
  • 4TOMSON T. Drug selection for the newly diagnosed patient : when is a new generation antiepileptic drug indicated? [J]. J Neurol,2004,251 (9):1043 - 1049.
  • 5MUKHIN KIU, GLUKHOVA LIU, PETRUKHIN AS,et al. Topamax in monotherapy of epilepsy [ J ]. Zh Nevropatol Psikhiatr,2004,104(8) :35 -40.
  • 6GILLIAM FG, VELOSO F, BOMHOF MA,et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy [J ]. Neurology, 2003,60 ( 2 ) : 196 - 202.
  • 7SALINAS-ESTABANE R. Topiramate monotherapy in adults with newly diagnosed epilepsy [J].Adv Ther, 2002, 19 (3) : 126 -128.
  • 8GUERRINI R, CARPAY J, GROSELJ J,et al. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting[J]. Seizure, 2005,14(6) :371 - 380.
  • 9ARROYO S, DODSON WE, PRIVITERA MD,et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy [ J]. Acta Neurol Scand, 2005,112(4 ) :214 - 222.
  • 10RESENDIZ-APARICIA JC, RODRIGUEZ-RODRIGUEZ E,CONTRERAS-BERNAL J,et al. A randomised open trial comparing monotherapy with topiramate versus carbamazepine in the treatment of paediatric patients with recently diagnosed epilepsy[ J]. Rev Neurol, 2004,39 (3) :201 - 204.

共引文献5

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部